Identification

Name
Bezafibrate
Accession Number
DB01393  (DB08380)
Type
Small Molecule
Groups
Approved
Description

Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. [PubChem]

Structure
Thumb
Synonyms
  • 2-(P-(2-(P-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
  • Befizal
  • Bezafibrat
  • Bezafibrato
  • Bezafibratum
  • Bezalip
  • Bezatol sr (tn)
  • Cedur
External IDs
BM 15.075
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act-bezafibrate SRTablet, extended release400 mgOralActavis Group Ptc Ehf.Not applicableNot applicableCanada
Bezalip SRTablet, extended release400 mgOralActavis Specialty Pharmaceuticals Co1994-12-21Not applicableCanada
Bezalip Tab 200mgTablet200 mgOralHoffmann La Roche1994-12-312001-07-19Canada
Jamp-bezafibrate SRTablet, extended release400 mgOralJamp Pharma Corporation2016-04-06Not applicableCanada
PMS-bezafibrateTablet200 mgOralPharmascience Inc1999-09-01Not applicableCanada
International/Other Brands
Befizal / Bezalip / Bezalip retard / Bezatol / Bezatol SR / Cedur
Categories
UNII
Y9449Q51XH
CAS number
41859-67-0
Weight
Average: 361.819
Monoisotopic: 361.10808584
Chemical Formula
C19H20ClNO4
InChI Key
IIBYAHWJQTYFKB-UHFFFAOYSA-N
InChI
InChI=1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
IUPAC Name
2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid
SMILES
CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O

Pharmacology

Indication

For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).

Structured Indications
Pharmacodynamics

Bezafibrate is an antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins. Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. The activity of triglyceride lipases (lipoprotein lipase and hepatic lipoproteinlipase) involved in the catabolism of triglyceride-rich lipoproteins is increased by bezafibrate. In the course of the intensified degradation of triglyceride-rich lipoproteins (chylomicrons, VLDL) precursors for the formation of HDL are formed which explains an increase in HDL. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL-receptor-mediated lipoprotein catabolism. Elevated fibrinogen appears to be an important risk-factor, alongside the lipids, smoking and hypertension, in the development of atheroma. Fibrinogen plays an important role in viscosity, and therefore blood flow, and also appears to play an important role in thrombus development and lysability. Bezafibrate exerts an effect on thrombogenic factors. A significant decrease in elevated plasma fibrinogen levels can be achieved. This may lead, amongst other things, to a reduction in both blood and plasma viscosity. Inhibition of platelet aggregation has also been observed. A reduction in blood glucose concentration due to an increase in glucose tolerance has been reported in diabetic patients. In the same patients, the concentration of fasting and postprandial free fatty acids was reduced by bezafibrate.

Mechanism of action

Like the other fibrates, bezafibrate is an agonist of PPARα; some studies suggest it may have some activity on PPARγ and PPARδ as well.

TargetActionsOrganism
APeroxisome proliferator-activated receptor alpha
agonist
Human
APeroxisome proliferator-activated receptor delta
agonist
Human
APeroxisome proliferator-activated receptor gamma
agonist
Human
UNuclear receptor subfamily 1 group I member 2
partial agonist
Human
URetinoic acid receptor RXR-alpha
agonist
Human
URetinoic acid receptor RXR-beta
agonist
Human
URetinoic acid receptor RXR-gamma
agonist
Human
Absorption

Bezafibrate is almost completely absorbed after oral administration. The relative bioavailability of bezafibrate retard compared to the standard form is about 70%.

Volume of distribution
Not Available
Protein binding

94-96% of bezafibrate is bound to protein in human serum.

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

1-2 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Bezafibrate.Experimental
AcenocoumarolBezafibrate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideBezafibrate may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Bezafibrate.Approved, Investigational
AmiodaroneThe metabolism of Bezafibrate can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Bezafibrate.Approved, Investigational
AprepitantThe serum concentration of Bezafibrate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Bezafibrate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Bezafibrate can be decreased when combined with Atomoxetine.Approved
AtorvastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Atorvastatin.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Bezafibrate.Withdrawn
BoceprevirThe metabolism of Bezafibrate can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Bezafibrate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bezafibrate can be decreased when it is combined with Bosentan.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Bezafibrate.Experimental
CarbamazepineThe metabolism of Bezafibrate can be increased when combined with Carbamazepine.Approved, Investigational
CarbutamideBezafibrate may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Bezafibrate.Withdrawn
CeritinibThe serum concentration of Bezafibrate can be increased when it is combined with Ceritinib.Approved
CerivastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Cerivastatin.Withdrawn
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Bezafibrate.Approved
ChlorpropamideBezafibrate may increase the hypoglycemic activities of Chlorpropamide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Bezafibrate.Approved, Investigational
ClarithromycinThe metabolism of Bezafibrate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bezafibrate can be decreased when combined with Clemastine.Approved
ClorindioneBezafibrate may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Bezafibrate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Bezafibrate can be decreased when combined with Cobicistat.Approved
ColchicineBezafibrate may increase the myopathic rhabdomyolysis activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Bezafibrate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Bezafibrate can be decreased when combined with Crizotinib.Approved
CyclosporineCyclosporine may increase the nephrotoxic activities of Bezafibrate.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Bezafibrate can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Bezafibrate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Bezafibrate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Bezafibrate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bezafibrate can be decreased when combined with Delavirdine.Approved
DicoumarolBezafibrate may increase the anticoagulant activities of Dicoumarol.Approved
DihydroergotamineThe metabolism of Bezafibrate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Bezafibrate can be decreased when combined with Diltiazem.Approved
DiphenadioneBezafibrate may increase the anticoagulant activities of Diphenadione.Experimental
DoxycyclineThe metabolism of Bezafibrate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Bezafibrate can be decreased when combined with Dronedarone.Approved
EnzalutamideThe serum concentration of Bezafibrate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Bezafibrate can be decreased when combined with Erythromycin.Approved, Vet Approved
Ethyl biscoumacetateBezafibrate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EzetimibeThe risk or severity of adverse effects can be increased when Bezafibrate is combined with Ezetimibe.Approved
FluconazoleThe metabolism of Bezafibrate can be decreased when combined with Fluconazole.Approved
FluindioneBezafibrate may increase the anticoagulant activities of Fluindione.Investigational
FluvastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Fluvastatin.Approved
FluvoxamineThe metabolism of Bezafibrate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Bezafibrate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bezafibrate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Bezafibrate can be increased when combined with Fosphenytoin.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Bezafibrate.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Bezafibrate can be increased when it is combined with Fusidic Acid.Approved
GlibornurideBezafibrate may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBezafibrate may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideBezafibrate may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBezafibrate may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBezafibrate may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideBezafibrate may increase the hypoglycemic activities of Glyburide.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Bezafibrate.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Bezafibrate.Experimental
IdelalisibThe serum concentration of Bezafibrate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Bezafibrate can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Bezafibrate can be decreased when combined with Indinavir.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Bezafibrate.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bezafibrate.Withdrawn
IsavuconazoniumThe metabolism of Bezafibrate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Bezafibrate.Approved
IsradipineThe metabolism of Bezafibrate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Bezafibrate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bezafibrate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Bezafibrate can be decreased when combined with Ketoconazole.Approved, Investigational
LopinavirThe metabolism of Bezafibrate can be decreased when combined with Lopinavir.Approved
LovastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Bezafibrate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Bezafibrate can be increased when combined with Lumacaftor.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Bezafibrate.Withdrawn
MetahexamideBezafibrate may increase the hypoglycemic activities of Metahexamide.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Bezafibrate.Approved, Investigational
MevastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Mevastatin.Experimental
MifepristoneThe serum concentration of Bezafibrate can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Bezafibrate.Approved
MitotaneThe serum concentration of Bezafibrate can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bezafibrate.Approved
NefazodoneThe metabolism of Bezafibrate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bezafibrate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Bezafibrate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bezafibrate can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Bezafibrate.Withdrawn
NilotinibThe metabolism of Bezafibrate can be decreased when combined with Nilotinib.Approved, Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bezafibrate.Withdrawn
OlaparibThe metabolism of Bezafibrate can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Bezafibrate can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Bezafibrate can be increased when it is combined with Palbociclib.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Bezafibrate.Approved
PentobarbitalThe metabolism of Bezafibrate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bezafibrate.Approved
PhenindioneBezafibrate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Bezafibrate.Withdrawn
PhenobarbitalThe metabolism of Bezafibrate can be increased when combined with Phenobarbital.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Bezafibrate.Withdrawn
PhenprocoumonBezafibrate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe metabolism of Bezafibrate can be increased when combined with Phenytoin.Approved, Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Bezafibrate.Approved
PitavastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Pitavastatin.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Bezafibrate.Withdrawn
PosaconazoleThe metabolism of Bezafibrate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin.Approved
PrimidoneThe metabolism of Bezafibrate can be increased when combined with Primidone.Approved, Vet Approved
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Bezafibrate.Approved
RanolazineThe metabolism of Bezafibrate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bezafibrate.Approved
RifabutinThe metabolism of Bezafibrate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bezafibrate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bezafibrate can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Bezafibrate can be decreased when combined with Ritonavir.Approved, Investigational
RosuvastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Rosuvastatin.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Bezafibrate.Withdrawn
SaquinavirThe metabolism of Bezafibrate can be decreased when combined with Saquinavir.Approved, Investigational
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Bezafibrate.Approved, Investigational, Vet Approved
SildenafilThe metabolism of Bezafibrate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Bezafibrate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bezafibrate can be increased when it is combined with Simeprevir.Approved
SimvastatinBezafibrate may increase the myopathic rhabdomyolysis activities of Simvastatin.Approved
St. John's WortThe serum concentration of Bezafibrate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Bezafibrate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Bezafibrate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Bezafibrate is combined with Sulpiride.Approved, Investigational
TelaprevirThe metabolism of Bezafibrate can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Bezafibrate can be decreased when combined with Telithromycin.Approved
TiclopidineThe metabolism of Bezafibrate can be decreased when combined with Ticlopidine.Approved
TioclomarolBezafibrate may increase the anticoagulant activities of Tioclomarol.Experimental
TocilizumabThe serum concentration of Bezafibrate can be decreased when it is combined with Tocilizumab.Approved
TolazamideBezafibrate may increase the hypoglycemic activities of Tolazamide.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Bezafibrate.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Bezafibrate.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bezafibrate.Approved
UbidecarenoneBezafibrate may increase the myopathic rhabdomyolysis activities of Ubidecarenone.Approved, Experimental
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Bezafibrate.Approved, Investigational
VenlafaxineThe metabolism of Bezafibrate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Bezafibrate can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Bezafibrate can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinBezafibrate may increase the anticoagulant activities of Warfarin.Approved
ZiprasidoneThe metabolism of Bezafibrate can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000 Jul 4;102(1):21-7. [PubMed:10880410]
  2. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005 May 23;165(10):1154-60. [PubMed:15911729]
  3. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 3. [PubMed:15123532]
  4. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006 Apr 10;166(7):737-41. [PubMed:16606809]
External Links
Human Metabolome Database
HMDB15465
KEGG Drug
D01366
PubChem Compound
39042
PubChem Substance
46509188
ChemSpider
35728
BindingDB
28701
ChEBI
47612
ChEMBL
CHEMBL264374
Therapeutic Targets Database
DAP001182
PharmGKB
PA162364313
IUPHAR
2668
Guide to Pharmacology
GtP Drug Page
HET
PEM
Wikipedia
Bezafibrate
ATC Codes
C10AB02 — Bezafibrate
AHFS Codes
  • 24:06.06 — Fribic Acid Derivatives
PDB Entries
1iwh / 5x2s / 5x2t

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCarnitine Palmitoyltransferase II Deficiency / Very Long Chain Acyl Coa Dehydrogenase Deficiency1
2CompletedTreatmentType 2 Diabetes Mellitus1
2RecruitingOtherMitochondrial Diseases1
2RecruitingTreatmentAcute Depressive Episode / Bipolar Disorder (BD)1
2RecruitingTreatmentMixed hypercholesterolemia1
3Active Not RecruitingTreatmentHypercholesterolaemia1
3CompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
3RecruitingTreatmentPrimary Biliary Cirrhosis (PBC)1
3RecruitingTreatmentPrimary Biliary Cirrhosis (PBC) / Primary Sclerosing Cholangitis (PSC) / Secondary Sclerosing Cholangitis1
3Unknown StatusTreatmentCarnitine Palmitoyl Transferase 2 Deficiency1
4CompletedTreatmentAcute Myocardial Infarction (AMI)1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Hypercholesterolaemia1
Not AvailableCompletedTreatmentAdrenomyeloneuropathy / X-Linked Adrenoleukodystrophy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral400 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Bezalip 400 mg Sustained-Release Tablet1.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)186 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.00155 mg/mLALOGPS
logP3.97ALOGPS
logP3.99ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)3.83ChemAxon
pKa (Strongest Basic)-0.84ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.63 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity95.96 m3·mol-1ChemAxon
Polarizability37.53 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9246
Blood Brain Barrier+0.8773
Caco-2 permeable-0.5564
P-glycoprotein substrateSubstrate0.6325
P-glycoprotein inhibitor INon-inhibitor0.8387
P-glycoprotein inhibitor IINon-inhibitor0.7329
Renal organic cation transporterNon-inhibitor0.8161
CYP450 2C9 substrateNon-substrate0.7725
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7261
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.883
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5096
Ames testNon AMES toxic0.7749
CarcinogenicityNon-carcinogens0.7815
BiodegradationNot ready biodegradable0.9902
Rat acute toxicity2.4927 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9928
hERG inhibition (predictor II)Non-inhibitor0.6481
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-ad4511ba17ddb3a6b528
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03k9-0049000000-319540ed864d05b5a9e8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-65fad146d0a2b8cc3aeb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0uk9-1980000000-f98f5d510895c2946e24
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-1900000000-58a247b2b13eaf401a8a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-3900000000-82a7a949824b1efdbd18
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03k9-0049000000-e56612834951c9281537
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-54280ef14ba8e69fb8fb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fk9-1890000000-81049839e6d37ddb476a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0900000000-3ff4da4d943e21e1f3a1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-2900000000-d499986dc5288dfff06c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-62a3f94f91039648ffe1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0390000000-52f95c54ab1946e7c69f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0190000000-5257df29ed69050f426d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-ced0d5dcc71914483b64
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-849460edc8b9e96e9749
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-2392000000-f4f98f4b89b6ae9a88d1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-016r-0049000000-03924d783ef40666f558
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0019000000-58ff2df39e2672d16d49
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00n0-0945000000-47d515a6530eb8a46418
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-0900000000-5b8c8d881ef997da896b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-0900000000-aee3a31283069d780fdf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-1900000000-673255bfbbfc965f4660
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-2900000000-3dc6146a7815f02b2566
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0019000000-f9cec491196c09ca122d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00n0-0935000000-36d012b5f26656975242
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-0900000000-c01b867af88dc70e482e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-0900000000-5d6c1954d400ba6b4b3a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-1900000000-8a719c7882b35ef9cb54
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-2900000000-db13d869394c364ba607
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-016r-0049000000-27c256b6fd4b11f2a68a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-0900000000-a8a872a7835365dc4d41
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0079-1900000000-30327ebb215c779dcc3f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-016r-0049000000-23a7df2abaccf8e2ad58
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0039000000-c9963bd4cd1703531d68
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0079-3901000000-21ede76e25f4013d242c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0079-0913000000-a4eb50a87f9a6c722663

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Phenoxyacetic acid derivatives
Alternative Parents
4-halobenzoic acids and derivatives / Benzamides / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Alkyl aryl ethers / Chlorobenzenes / Aryl chlorides / Secondary carboxylic acid amides / Monocarboxylic acids and derivatives
show 7 more
Substituents
Phenoxyacetate / 4-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzoic acid or derivatives / Benzamide / Phenoxy compound / Phenol ether / Benzoyl / Chlorobenzene / Alkyl aryl ether
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, monocarboxylic acid, monocarboxylic acid amide, monochlorobenzenes (CHEBI:47612)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Pedraza N, Solanes G, Carmona MC, Iglesias R, Vinas O, Mampel T, Vazquez M, Giralt M, Villarroya F: Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene. Diabetes. 2000 Jul;49(7):1224-30. [PubMed:10909982]
  2. Cabrero A, Alegret M, Sanchez R, Adzet T, Laguna JC, Vazquez M: Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Arch Biochem Biophys. 2000 Aug 15;380(2):353-9. [PubMed:10933891]
  3. Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S: The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001 Jan;50(1):3-11. [PubMed:11172467]
  4. Guan Y, Breyer MD: Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001 Jul;60(1):14-30. [PubMed:11422732]
  5. Bonilla S, Redonnet A, Noel-Suberville C, Groubet R, Pallet V, Higueret P: Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver. J Physiol Biochem. 2001 Mar;57(1):1-8. [PubMed:11519881]
  6. Goldenberg I, Benderly M, Goldbourt U: Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag. 2008;4(1):131-41. [PubMed:18629356]
  7. Fruchart JC, Duriez P: Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64. [PubMed:16511610]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-lin...
Gene Name
PPARD
Uniprot ID
Q03181
Uniprot Name
Peroxisome proliferator-activated receptor delta
Molecular Weight
49902.99 Da
References
  1. Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005 Sep 16;4:14. [PubMed:16168052]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005 Sep 16;4:14. [PubMed:16168052]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Creusot N, Kinani S, Balaguer P, Tapie N, LeMenach K, Maillot-Marechal E, Porcher JM, Budzinski H, Ait-Aissa S: Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples. Anal Bioanal Chem. 2010 Jan;396(2):569-83. doi: 10.1007/s00216-009-3310-y. Epub 2009 Nov 29. [PubMed:20024649]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRA
Uniprot ID
P19793
Uniprot Name
Retinoic acid receptor RXR-alpha
Molecular Weight
50810.835 Da
References
  1. Sarath Josh MK, Pradeep S, Vijayalekshmi Amma KS, Balachandran S, Abdul Jaleel UC, Doble M, Spener F, Benjamin S: Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor alpha, beta, gamma subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11. [PubMed:23843199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRB
Uniprot ID
P28702
Uniprot Name
Retinoic acid receptor RXR-beta
Molecular Weight
56921.38 Da
References
  1. Sarath Josh MK, Pradeep S, Vijayalekshmi Amma KS, Balachandran S, Abdul Jaleel UC, Doble M, Spener F, Benjamin S: Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor alpha, beta, gamma subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11. [PubMed:23843199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRG
Uniprot ID
P48443
Uniprot Name
Retinoic acid receptor RXR-gamma
Molecular Weight
50870.72 Da
References
  1. Sarath Josh MK, Pradeep S, Vijayalekshmi Amma KS, Balachandran S, Abdul Jaleel UC, Doble M, Spener F, Benjamin S: Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor alpha, beta, gamma subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11. [PubMed:23843199]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292]

Drug created on July 08, 2007 11:01 / Updated on November 13, 2017 21:49